TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23043203

Group type: EXPERIMENTAL
Intervention: Free daily school breakfast programme (SBP)
Number of subjects: 424

Group type: COMPARATOR
Intervention: Control phase (no SBP)
Number of subjects: 424
Study: 20391093

Group type: EXPERIMENTAL
Intervention: Ten 30‐s passive knee flexor muscle stretches
Number of subjects: 20

Group type: COMPARATOR
Intervention: No stretching (control condition)
Number of subjects: 20
Study: 18581174

Group type: EXPERIMENTAL
Intervention: Nuclear shape factor analysis
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Intraobserver agreement
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Interobserver agreement
Number of subjects: 98
Study: 16527709

Group type: EXPERIMENTAL
Intervention: Laparoscopic myomectomy
Number of subjects: 148

Group type: COMPARATOR
Intervention: Minilaparotomic myomectomy
Number of subjects: 148
Study: 14639446

Group type: EXPERIMENTAL
Intervention: High-Intensity (HI; 70-80% heart rate reserve)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Low-Intensity (LI; 40-50% heart rate reserve)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Correlation between VO(2Peak) and insulin sensitivity
Number of subjects: 6
Study: 10634221

Group type: EXPERIMENTAL
Intervention: Lactobacillus GG
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9052319

Group type: EXPERIMENTAL
Intervention: Interactive computer learning (RELAX software)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Textbook learning
Number of subjects: 23
Study: 8245278

Group type: EXPERIMENTAL
Intervention: Neuropsychological remediation tasks (n = 15)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ecologically relevant tasks (n = 15)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Attention-placebo tasks (n = 16)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No intervention (n = 15)
Number of subjects: 60
Study: 3895539

Group type: EXPERIMENTAL
Intervention: Donor-specific transfusions (DST) combined with conventional immunosuppressive therapy (azathioprine, prednisone, and antilymphoblast globulin)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Cyclosporine and prednisone without DST
Number of subjects: 49

Group type: COMPARATOR
Intervention: Cyclosporine without prior DST
Number of subjects: 49
Study: 30739167

Group type: EXPERIMENTAL
Intervention: Sprint Interval Training (SIT)
Number of subjects: 30
Study: 29310631

Group type: EXPERIMENTAL
Intervention: 1 g CTE in 400 mL of water
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 2 g CTE in 400 mL of water
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 1 g CTE with 50 g sucrose in 400 mL of water
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 2 g CTE with 50 g sucrose in 400 mL of water
Number of subjects: 15

Group type: COMPARATOR
Intervention: 50 g sucrose in 400 mL water
Number of subjects: 15
Study: 26540622

Group type: EXPERIMENTAL
Intervention: Current cervical cancer screening guidelines
Number of subjects: 1268
Study: 24385331

Group type: EXPERIMENTAL
Intervention: Post-discharge nurse-led telephone support
Number of subjects: 135

Group type: COMPARATOR
Intervention: Routine hospital discharge care (Control)
Number of subjects: 135
Study: 22486584

Group type: EXPERIMENTAL
Intervention: Mountain hiking (9-week hiking phase)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control phase (9-week control phase)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Mountain hiking (within the hiking phase)
Number of subjects: 20
Study: 20412139

Group type: EXPERIMENTAL
Intervention: Lupine flour (DBPCFC)
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: Lupine flour (dietary record)
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: Sensitization to lupine flour
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: Specific IgE measurement
Number of subjects: 372
Study: 17698901

Group type: EXPERIMENTAL
Intervention: Low total testosterone (<300 ng/dl)
Number of subjects: 1475

Group type: EXPERIMENTAL
Intervention: Low free testosterone (<5 ng/dl)
Number of subjects: 1475

Group type: EXPERIMENTAL
Intervention: Symptoms of androgen deficiency
Number of subjects: 1475

Group type: EXPERIMENTAL
Intervention: Symptomatic androgen deficiency
Number of subjects: 1475

Group type: EXPERIMENTAL
Intervention: Age-related prevalence of symptomatic androgen deficiency
Number of subjects: 1475
Study: 12771037

Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA), 4 g daily for 3 months
Number of subjects: 42

Group type: COMPARATOR
Intervention: Oleic acid (OA), 4 g daily for 3 months
Number of subjects: 42
Study: 11145387

Group type: EXPERIMENTAL
Intervention: Total hip arthroplasty (Lubinus IP)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Osteosynthesis with two parallel and percutaneously inserted screws (Olmed)
Number of subjects: 100
Study: 9768319

Group type: EXPERIMENTAL
Intervention: CO2 detection task
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: CO2-induced transient disruption of respiratory pattern
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: CO2 detection threshold
Number of subjects: 20
Study: 8463443

Group type: EXPERIMENTAL
Intervention: Imipramine (maximum dose of 300 mg per day)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 4087830

Group type: EXPERIMENTAL
Intervention: Oral rifampicin (600 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intravenous rifampicin (600 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oral and intravenous rifampicin therapy
Number of subjects: 12
Study: 30917064

Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (tDCS) to left prefrontal cortex
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (tDCS) to left primary motor cortex (M1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (tDCS) to right prefrontal cortex
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham stimulation (control group)
Number of subjects: 0
Study: 27885522

Group type: EXPERIMENTAL
Intervention: Fractional CO2 laser
Number of subjects: 40

Group type: COMPARATOR
Intervention: Fractional Er:YAG laser
Number of subjects: 40
Study: 26514478

Group type: EXPERIMENTAL
Intervention: Group education based on the Health Belief Model
Number of subjects: 120

Group type: COMPARATOR
Intervention: Multimedia education based on the Health Belief Model
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Both educational methods
Number of subjects: 120
Study: 23320436

Group type: EXPERIMENTAL
Intervention: 50 mg gemigliptin qd
Number of subjects: 425

Group type: COMPARATOR
Intervention: 100 mg sitagliptin qd
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: 25 mg gemigliptin bid
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: gemigliptin treatment
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: gemigliptin
Number of subjects: 425
Study: 21918474

Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 984

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 984
Study: 19145494

Group type: EXPERIMENTAL
Intervention: Fesoterodine 4 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Fesoterodine 8 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Fesoterodine 12 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Fesoterodine 8 mg after high-fat breakfast
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: CYP2D6 poor metabolisers
Number of subjects: 24

Group type: COMPARATOR
Intervention: Tolterodine (for comparison)
Number of subjects: 24
Study: 17760242

Group type: EXPERIMENTAL
Intervention: New fixator group (n=25)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard dressing group (n=25)
Number of subjects: 50
Study: 15259543

Group type: EXPERIMENTAL
Intervention: Active desensitizing agent (UltraEZ) applied daily for 14 days prior to whitening for 30 minutes.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (same formulation as UltraEZ without desensitizing agents) applied daily for 14 days prior to whitening for 30 minutes.
Number of subjects: 40
Study: 11078068

Group type: EXPERIMENTAL
Intervention: Prophylactic perioperative prednisolone treatment
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control group (no prednisolone treatment)
Number of subjects: 95
Study: 8957021

Group type: EXPERIMENTAL
Intervention: IVIg
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 1555812

Group type: EXPERIMENTAL
Intervention: Single dose of hydroxyzine (10 mg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Single dose of buspirone (5 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Multi-dose of buspirone (5 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Multi-dose of chlordiazepoxide (5 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Multi-dose of hydroxyzine (10 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: EEG analysis
Number of subjects: 9
Study: 3894589

Group type: COMPARATOR
Intervention: Cisplatin 50 mg/m2 every 21 days (regimen 1)
Number of subjects: 497

Group type: EXPERIMENTAL
Intervention: Cisplatin 100 mg/m2 every 21 days (regimen 2)
Number of subjects: 497

Group type: EXPERIMENTAL
Intervention: Cisplatin 20 mg/m2 for five consecutive days repeated every 21 days (regimen 3)
Number of subjects: 497
Study: 30977393

Group type: EXPERIMENTAL
Intervention: Eftilagimod alpha (IMP321) plus paclitaxel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Paclitaxel plus placebo
Number of subjects: 0
Study: 29368349

Group type: EXPERIMENTAL
Intervention: Antera 3D
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Large filter of Antera 3D
Number of subjects: 26

Group type: COMPARATOR
Intervention: DermaTOP
Number of subjects: 26

Group type: COMPARATOR
Intervention: Parallel-polarized photographs
Number of subjects: 26
Study: 27328954

Group type: EXPERIMENTAL
Intervention: Left TRA
Number of subjects: 150

Group type: COMPARATOR
Intervention: Right TRA
Number of subjects: 150

Group type: COMPARATOR
Intervention: TFA
Number of subjects: 150
Study: 24336385

Group type: EXPERIMENTAL
Intervention: Multiple-family intervention (MUFI)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Single-family intervention (SIFI)
Number of subjects: 97
Study: 23558369

Group type: EXPERIMENTAL
Intervention: Fascia iliaca block (30 mL 0.5% ropivacaine)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Sham block (30 mL 0.9% NaCl)
Number of subjects: 32
Study: 19920766

Group type: EXPERIMENTAL
Intervention: Clarithromycin (500 mg daily for 2 weeks)
Number of subjects: 4373

Group type: COMPARATOR
Intervention: Matching placebo (daily for 2 weeks)
Number of subjects: 4373
Study: 18971523

Group type: EXPERIMENTAL
Intervention: Azelnidipine 8 mg monotherapy
Number of subjects: 223

Group type: COMPARATOR
Intervention: Temocapril 2 mg monotherapy
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Combination therapy (azelnidipine and temocapril)
Number of subjects: 223
Study: 16650580

Group type: EXPERIMENTAL
Intervention: Methylprednisolone 125 mg
Number of subjects: 219

Group type: COMPARATOR
Intervention: Parecoxib 40 mg
Number of subjects: 219

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 219
Study: 12855059

Group type: EXPERIMENTAL
Intervention: Successful treatments (psychotherapy)
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (briefest treatments)
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Naturalistic study of successful treatments
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Effectiveness research
Number of subjects: 242

Group type: COMPARATOR
Intervention: Efficacy trials
Number of subjects: 242
Study: 10999803

Group type: EXPERIMENTAL
Intervention: Metformin (500 mg x 2 daily for 3 months, then 1,000 mg x 2 daily for 3 months)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Diane Nova (ethinyl estradiol 35 microg-cyproterone acetate 2 mg)
Number of subjects: 32
Study: 8791947

Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate 400 mg b.d. plus clarithromycin 500 mg t.d.s. for the first 2 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate 400 mg b.d. for 4 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clarithromycin 500 mg t.d.s. for the first 2 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 0
Study: 1281625

Group type: EXPERIMENTAL
Intervention: Epidural morphine
Number of subjects: 55

Group type: COMPARATOR
Intervention: Epidural hydromorphone
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Epidural morphine and hydromorphone
Number of subjects: 55
Study: 31424649

Group type: EXPERIMENTAL
Intervention: simple intravenous chemotherapy with cisplatin paclitaxel (TP group)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: gene therapy + intravenous chemotherapy with cisplatin+paclitaxel (rAd‐p53 + TP group)
Number of subjects: 80

Group type: COMPARATOR
Intervention: radical hysterectomy (RH group)
Number of subjects: 80
Study: 28540480

Group type: EXPERIMENTAL
Intervention: Four-phasic injection protocol (saline pacer bolus of 10 ml before three-phasic protocol)
Number of subjects: 2445

Group type: COMPARATOR
Intervention: Three-phasic injection protocol (CM bolus of 85 ml, followed by 40 ml saline/CM mixture, and 30 ml saline chaser)
Number of subjects: 2445
Study: 26502235

Group type: COMPARATOR
Intervention: Control group (chlorhexidine and resin‐modified glass ionomer cement)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: LEDTB group (photodynamic antimicrobial chemotherapy with light‐emitting diode and toluidine blue solution and RMGIC)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: LMB group (photodynamic antimicrobial chemotherapy with laser and methylene blue solution and RMGIC)
Number of subjects: 32
Study: 23839029

Group type: EXPERIMENTAL
Intervention: Oral oxycodone (high dose 45 mg/70 kg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oral oxycodone (low dose 15 mg/70 kg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oral morphine (high dose 135 mg/70 kg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oral morphine (low dose 45 mg/70 kg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: COMPARATOR
Intervention: Money
Number of subjects: 12
Study: 21793378

Group type: EXPERIMENTAL
Intervention: A-M plasma group (A-M-P)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: NA-M plasma group (NA-M-P)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study: 22025101

Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 228

Group type: COMPARATOR
Intervention: Self-care book
Number of subjects: 228

Group type: COMPARATOR
Intervention: Conventional stretching exercises
Number of subjects: 228
Study: 17401004

Group type: EXPERIMENTAL
Intervention: Chemoradiation followed by surgery (arm A)
Number of subjects: 259

Group type: COMPARATOR
Intervention: Continuation of chemoradiation (arm B)
Number of subjects: 259
Study: 16253169

Group type: EXPERIMENTAL
Intervention: Late course conformal radiotherapy combined with chemotherapy
Number of subjects: 96

Group type: COMPARATOR
Intervention: Conventional radiotherapy
Number of subjects: 96
Study: 12012943

Group type: EXPERIMENTAL
Intervention: Healthy & Vital (health education and low-intensity exercises)
Number of subjects: 50
Study: 10215713

Group type: EXPERIMENTAL
Intervention: Propofol 2.5 mg.kg‐1
Number of subjects: 120

Group type: COMPARATOR
Intervention: Thiopentone 5 mg.kg‐1
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg.kg‐1 with Propofol
Number of subjects: 120

Group type: COMPARATOR
Intervention: Rocuronium 0.6 mg.kg‐1 with Thiopentone
Number of subjects: 120
Study: 8550649

Group type: EXPERIMENTAL
Intervention: Inexpensive running shoes
Number of subjects: 39

Group type: COMPARATOR
Intervention: Leather-soled Oxford-style shoes
Number of subjects: 39

Group type: COMPARATOR
Intervention: Thin socks
Number of subjects: 39
Study: 2194032

Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Enalapril 5 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 389843

Group type: EXPERIMENTAL
Intervention: Fluocinonide 0.05% emollient cream
Number of subjects: 240

Group type: COMPARATOR
Intervention: Betamethasone valerate 0.1% cream
Number of subjects: 240

Group type: COMPARATOR
Intervention: Triamcinolone acetonide 0.1% cream
Number of subjects: 240
Study: 30302901

Group type: COMPARATOR
Intervention: Intralesional triamcinolone acetonide (TRA) injection
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Combined intralesional injection of TRA and pentoxifylline (PTX)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Intralesional pentoxifylline (PTX) injection
Number of subjects: 75
Study: 27759579

Group type: EXPERIMENTAL
Intervention: Magnesium supplementation (600 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 25701560

Group type: EXPERIMENTAL
Intervention: 2+1 group (two-dose prime and boost)
Number of subjects: 390
Study: 23599118

Group type: EXPERIMENTAL
Intervention: Topical anakinra, 2.5% (n = 30)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Topical anakinra, 5% (n = 15)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Vehicle (1% carboxymethylcellulose) (n = 30)
Number of subjects: 75
Study: 20693429

Group type: EXPERIMENTAL
Intervention: High-dose daunorubicin (50 mg/m² daily for 5 days) + cytarabine (100 mg/m² daily for 7 days)
Number of subjects: 1057

Group type: COMPARATOR
Intervention: Standard-dose idarubicin (12 mg/m² daily for 3 days) + cytarabine (100 mg/m² daily for 7 days)
Number of subjects: 1057

Group type: EXPERIMENTAL
Intervention: High-dose daunorubicin
Number of subjects: 1057

Group type: COMPARATOR
Intervention: Standard-dose idarubicin
Number of subjects: 1057
Study: 19318972

Group type: EXPERIMENTAL
Intervention: Adjunctive aripiprazole
Number of subjects: 679

Group type: COMPARATOR
Intervention: Adjunctive placebo
Number of subjects: 679
Study: 16445701

Group type: EXPERIMENTAL
Intervention: Heparin treatment
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 62
Study: 15514727

Group type: EXPERIMENTAL
Intervention: Refracterin, 300 mg/day for 3 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11524065

Group type: EXPERIMENTAL
Intervention: Aspirin 160 mg
Number of subjects: 6021

Group type: COMPARATOR
Intervention: Aspirin 80 mg + Warfarin 1 mg
Number of subjects: 6021
Study: 9302908

Group type: EXPERIMENTAL
Intervention: Sinus irrigation followed by functional endoscopic sinus surgery (FESS)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Sinus irrigation alone
Number of subjects: 89
Study: 8440842

Group type: EXPERIMENTAL
Intervention: Forward order presentation of survival curves
Number of subjects: 166

Group type: COMPARATOR
Intervention: Backward order presentation of survival curves
Number of subjects: 166
Study: 3546420

Group type: EXPERIMENTAL
Intervention: 2% topical ketoconazole cream (once or twice daily)
Number of subjects: 60
Study: 31930949

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) applied to one donor site
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no PRP)
Number of subjects: 24
Study: 27738812

Group type: EXPERIMENTAL
Intervention: Green/roasted coffee blend (35/65), 3 servings/day providing 510.6 mg hydroxycinnamic acids and 121.2 mg caffeine/day for 8 weeks
Number of subjects: 52
Study: 27257953

Group type: EXPERIMENTAL
Intervention: Oxandrolone 0.1 mg/kg/day in MCT oil
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Oxandrolone 0.2 mg/kg/day aqueous solution
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Oxandrolone 0.1 mg/kg/day aqueous solution
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (no oxandrolone)
Number of subjects: 15
Study: 24930327

Group type: EXPERIMENTAL
Intervention: Vacuum shoe system
Number of subjects: 20

Group type: COMPARATOR
Intervention: Forefoot unloading shoe
Number of subjects: 20
Study: 23768129

Group type: EXPERIMENTAL
Intervention: Ipsilateral acupuncture
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Contralateral acupuncture
Number of subjects: 45

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 45
Study: 20837289

Group type: EXPERIMENTAL
Intervention: Photoelectric alarms with lithium batteries
Number of subjects: 691

Group type: EXPERIMENTAL
Intervention: Ionizing alarms with lithium batteries
Number of subjects: 691

Group type: EXPERIMENTAL
Intervention: Photoelectric alarms with zinc batteries
Number of subjects: 691

Group type: EXPERIMENTAL
Intervention: Ionizing alarms with zinc batteries
Number of subjects: 691
Study: 18392866

Group type: EXPERIMENTAL
Intervention: Intervention
Number of subjects: 253

Group type: COMPARATOR
Intervention: Control
Number of subjects: 253
Study: 15850466

Group type: EXPERIMENTAL
Intervention: Lamivudine, 100 mg, qd, for 12 months
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Lamivudine-interferon (9 MU, t.i.w.) in combination
Number of subjects: 78
Study: 12553110

Group type: EXPERIMENTAL
Intervention: Macrolide antibiotics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no antibiotic treatment)
Number of subjects: 0
Study: 10509062

Group type: EXPERIMENTAL
Intervention: Standing flexion test performed by nine examiners
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Standing flexion test performed by the same examiners
Number of subjects: 9
Study: 7587975

Group type: EXPERIMENTAL
Intervention: Selegiline (10 mg, p.o.)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 1974561

Group type: EXPERIMENTAL
Intervention: loratadine (10 mg once daily)
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study: 7195931

Group type: EXPERIMENTAL
Intervention: Standard milk‐based formula
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard milk‐based formula with iron
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Soy‐based formula with iron
Number of subjects: 0
Study: 31097383

Group type: EXPERIMENTAL
Intervention: ezetimibe 10 mg
Number of subjects: 87

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 87
Study: 29526502

Group type: EXPERIMENTAL
Intervention: Alirocumab 150 mg or 75/150 mg every two weeks
Number of subjects: 4629

Group type: COMPARATOR
Intervention: Control (placebo or ezetimibe)
Number of subjects: 4629

Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 4629